General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-04-25 | 2024-03 | 2.61 | N/A | N/A | N/A |
2024-02-06 | 2023-12 | 2.47 | 2.49 | 0.02 | 0.81% |
2023-11-02 | 2023-09 | -0.08 | 0.1 | 0.18 | 225.00% |
2023-08-08 | 2023-06 | 1.98 | 2.11 | 0.13 | 6.57% |
2023-04-27 | 2023-03 | 1.73 | 1.62 | -0.11 | -6.36% |
2023-02-02 | 2022-12 | 1.83 | 2.09 | 0.26 | 14.21% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-10 | Morgan Stanley | Upgrade | Overweight | Overweight |
2023-10-08 | Wells Fargo | Upgrade | Overweight | Overweight |
2023-10-08 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-10-01 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-09-04 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-09-04 | Morgan Stanley | Upgrade | Overweight | Overweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-03-17 | ALVAREZ RALPH | Director | 54.01K | Stock Award(Grant) |
2024-02-11 | HAKIM ANAT | General Counsel | 30.48K | Stock Award(Grant) |
2024-03-17 | HEDLEY MARY LYNNE | Director | 1.56K | Stock Award(Grant) |
2024-03-17 | JOHNSON KIMBERLY H | Director | 2.61K | Stock Award(Grant) |
2024-02-15 | LILLY ENDOWMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | 98.90M | Sale |
2024-03-17 | LUCIANO JUAN R | Director | 15.66K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-09-29 | Lilly Endowment, Inc | 99.98M | 53.70B | 10.53% |
2023-06-29 | Vanguard Group Inc | 69.92M | 32.79B | 7.37% |
2023-06-29 | Blackrock Inc. | 64.45M | 30.23B | 6.79% |
2023-06-29 | PNC Financial Services Group, Inc. | 51.87M | 24.33B | 5.46% |
2023-06-29 | State Street Corporation | 33.88M | 15.89B | 3.57% |
2023-06-29 | FMR, LLC | 32.80M | 15.38B | 3.46% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 26.65M | 12.50B | 2.81% |
2023-06-29 | Vanguard 500 Index Fund | 18.76M | 8.80B | 1.98% |
2023-06-29 | Vanguard/Primecap Fund | 13.35M | 6.26B | 1.41% |
2023-05-30 | Fidelity 500 Index Fund | 8.83M | 3.79B | 0.93% |
2023-08-30 | SPDR S&P 500 ETF Trust | 8.68M | 4.81B | 0.91% |
2023-08-30 | iShares Core S&P 500 ETF | 7.37M | 4.08B | 0.78% |
Dividend | Date |
---|---|
1.3 | 2024-02-15 |
1.3 | 2024-02-14 |
1.13 | 2023-11-14 |
1.13 | 2023-09-08 |
1.13 | 2023-08-14 |
1.13 | 2023-05-12 |
Split | Date |
---|---|
2 : 1 | 1997-10-16 |
2 : 1 | 1995-12-21 |
2 : 1 | 1989-05-01 |
2 : 1 | 1986-01-30 |
$LLY My Nephew works here and I ask all the time for details and he only says “buy all you can uncle
$LLY My Nephew works here and I ask all the time for details and he only says “buy all you can uncle
$LLY My Nephew works here and I ask all the time for details and he only says “buy all you can uncle”
$LLY Best of Breed Bitches. Viking is phase 2 years away. We are King in 5 categories. Going much higher soon.
$LLY Numerous Approvals Any Day Now
$LLY Best of Breed in Numerous Groundbreaking Areas! Alzheimers, Weight Loss, Diabetes, Liver Disease, Heart. Best!
$LLY Best Of Breed in 5 Major Categories
$LLY You have to be an Idiot to short he with Numerous Pending FDA Approvals in Life Changing Drugs. Weight Loss, Diabetes, Fatty Liver, Alzheimer’s and more. $1,700 in a year….
Looks like someone just bought 100K of $LLY 🤩
Nancy is that you?!
$LLY Oversold here. Buying with both hands!
$LLY Only a Fool would be selling here. This stock will be $1,500+ in a year….
$LLY Shorts will be destroyed when numerous drug approvals come through soon….
$LLY Novo in stage 1. Years off. Lilly Best of Breed
$LLY , NVO Is in stage 1. Years away. Oversold
$LLY Shorts will be wiped out when any one of the 4 drug approval’s get announced any days now…
$LLY Approvals any day now. See you at $1,000+
$LLY
Bank of America raises Eli Lilly price target to $1,000 per share from $800 on margin expansion expectations and compelling pipeline. That PT would bring the Club name just shy of a $1 trillion market value. Lilly has built a wide moat around its GLP-1s (Zepbound for obesity and Mounjaro for diabetes) due to the billions of dollars it's invested in capacity.
$LLY UPGRADE:
Bank of America sees more upside potential ahead for weight loss drug manufacturer
There’s more growth ahead for Eli Lilly, according to Bank of America.
The bank lifted its price target on the buy-rated biopharma stock to $1,000 from $800. This implies that shares of Eli Lilly could rise 33% from their Thursday closing price of $753.68.
The stock has already rallied 29% this year, but analyst Geoff Meacham justified potential upside ahead that could come as shares of Eli Lilly strengthen amid a “scarcity of high growth stories in Healthcare.”
“Lilly remains a favorite name in our Biopharma coverage, even with strong YTD performance, based on peer-leading revenue growth, margin expansion, and a compelling pipeline,” he added. “While investors clearly recognize the commercial opportunity for Mounjaro (diabetes) and Zepbound (obesity), we’d argue that additional opportunities in heart disease (HFpEF; phase 3), obstructive sleep apnea (OSA; phase 3), and liver disease (NASH; phase 2) are vastly underappreciated.”
The analyst believes that by 2030, sales of tirzepatide — the active ingredient in Mounjaro — could top $60 billion from $15 billion in 2024. Although Eli Lilly faces hefty competition, Meacham is confident in the company’s competitive advantages over its peers.
“We suspect investors discount Lilly + Novo’s substantial expertise in the space, which together with a lack of available manufacturing capacity, create very high competitive hurdles,” he wrote.